Abstract
DBA/2 and C57BL/6 are two commonly used mouse strains that differ in response to nicotine. Previous studies have shown that the nicotine-metabolizing enzyme CYP2A5 differs in coumarin metabolism between these two strains, suggesting differences in nicotine metabolism. Nicotine was metabolized to cotinine in vitro by two enzymatic sites. The high-affinity sites exhibited similar parameters (Km, 10.7 ± 4.8 versus 11.4 ± 3.6 μM; Vmax, 0.58 ± 0.18 versus 0.50 ± 0.07 nmol/min/mg for DBA/2 and C57BL/6, respectively). In vivo, the elimination halflives of nicotine (1 mg/kg, s.c.) were also similar between DBA/2 and C57BL/6 mice (8.6 ± 0.4 versus 9.2 ± 1.6 min, respectively); however, cotinine levels were much higher in DBA/2 mice. The production and identity of the putative cotinine metabolite 3′-hydroxycotinine in mice was confirmed by liquid chromatography/mass spectrometry/mass spectrometry. The in vivo half-life of cotinine (1 mg/kg, s.c.) was significantly longer in the DBA/2 mice compared with the C57BL/6 mice (50.2 ± 4.7 versus 37.5 ± 9.6 min, respectively, p < 0.05). The in vitro metabolism of cotinine to 3′-hydroxycotinine was also less efficient in DBA/2 than C57BL/6 mice (Km, 51.0 ± 15.6 versus 9.5 ± 2.1 μM, p < 0.05; Vmax, 0.10 ± 0.01 versus 0.04 ± 0.01 nmol/min/mg, p < 0.05, respectively). Inhibitory antibody studies demonstrated that the metabolism of both nicotine and cotinine was mediated by CYP2A5. Genetic differences in Cyp2a5 potentially contributed to similar nicotine but different cotinine metabolism, which may confound the interpretation of nicotine pharmacological studies and studies using cotinine as a biomarker.
Footnotes
-
This study was supported by Centre for Addiction & Mental Health and Canadian Institutes of Health Research grant number MOP 53248. Canadian Institutes of Health Research-Special Training Program in Tobacco Control and Ontario Graduate Scholarship Program (to E.C.K.S.) and Canada Research Chair in Pharmacogenetics (to R.F.T.).
-
R.F.T. is a shareholder and chief scientific officer of Nicogen Inc., a company focused on the development of novel smoking cessation therapies; no funds were received from Nicogen for these studies, and the manuscript was not reviewed by other people associated with Nicogen before submission or revision.
-
Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org.
-
doi:10.1124/mol.106.032086.
-
ABBREVIATIONS: HPLC, high-performance liquid chromatography; MS, mass spectrometry; LC, liquid chromatography; EMS, enhanced mass scan; AUC, area under the concentration; Cmax, maximum concentration; Tmax, time at maximum concentration; CL, clearance; F, bioavailability; NNK, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone.
- Received October 20, 2006.
- Accepted December 6, 2006.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|